Eli Lilly and Company

NYSE:LLY

Drug Manufacturers - General

Healthcare
$1,382.54 -0.95%

-$10.54 today

Market cap
$1.30T
Beta
0.52
P/E (TTM)
39.0
EPS (TTM)
$28.26
Dividend yield
0.59%
52W Low $623.78High $1,182.73

Volume 2.58M

Average 3.19M

LLY Total Non-current Assets

All assets not expected to be converted to cash within one year.

Eli Lilly and CompanyNYSE: LLY

Total Non-current Assets · Q2 FY2026 · quarter ended Jun 2026

Total non-current assets rises 52.0% from a year ago

Total non-current assets stood at $77.61B at the end of Q2 FY2026, up 52.0% from a year earlier and up 25.7% from the prior quarter. Over 3 fiscal years it compounded at +21.8% a year.

Context

  • Total non-current assets amounted to 54.5% of total assets at the end of Q2 FY2026, up 3.9 pp from a year earlier.
  • Total non-current assets increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total non-current assets keeps rising in the next quarterly balance sheet after a +52.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$77.61B+25.7% QoQ
Last fiscal yearDec 2025
$56.85B+23.6% YoY
Year agoJun 2025
$51.07B+52.0% since
Total Non-current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+52.0%——
1 year+23.6%——
3-year CAGR+21.8%——
5-year CAGR——
10-year CAGR——

Total Non-current Assets history

USD · from the balance sheet

Latest · FY2025
56.85B USD
Year-over-year change
+23.6%
4-year CAGR
+17.0%

Total Non-current Assets vs competitors

How LLY compares with its peers on the latest reported figures

  • Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +52.0% is the highest of 10, against a peer median of +4.5%.
  • Total non-current assets amounts to 54.5% of total assets for LLY, versus a peer median of 73.8%.
LLY Competitors
Total Non-current Assets for LLY and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NVONovo Nordisk A/SJun 2026DKK 386.25B DKK+20.9%+40.7%64.9%
PFEPfizer Inc.Jun 2026$159.77B USD-1.6%+4.2%79.4%
JNJJohnson & JohnsonSep 2026$141.07B USD+2.1%+2.8%71.5%
ABBVAbbVie Inc.Jun 2026$101.45B USD-6.0%-1.7%75.1%
SNYSanofiJun 2026€97.54B EUR+10.9%+1.1%75.6%
NVSNovartis AGJun 2026$94.68B USD+20.7%+1.9%77.6%
MRKMerck & Co., Inc.Jun 2026$93.12B USD+15.7%+8.3%71.7%
AZNAstraZeneca PLCSep 2026$88.32B USD+4.5%+4.9%73.8%
LLYEli Lilly and CompanyJun 2026$77.61B USD+52.0%+21.8%54.5%
AMGNAmgen Inc.Jun 2026$60.68B USD-0.8%+12.7%63.4%
Peer median (excluding LLY) —+4.5%+4.2%73.8%

Competitors are the stored peer set for LLY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents3.82B2.07B2.82B3.27B7.16B
Short-term Investments90.1M144.8M109.1M154.8M105M
Net Receivables8.13B8.56B11.34B13.28B20.16B
Inventory3.89B4.31B5.77B7.59B13.74B
Other Current Assets07.3M149.5M111.4M147M
Total Current Assets18.45B18.03B25.73B32.74B55.63B
Property, Plant & Equipment (Net)8.99B10.14B12.91B17.1B24.68B
Goodwill3.89B4.07B4.94B5.77B5.9B
Intangible Assets7.69B7.21B6.91B6.17B6.52B
Long-term Investments3.21B2.9B3.05B3.22B2.8B
Tax Assets2.49B2.79B5.48B8B9.96B
Other Non-current Assets4.08B4.34B4.99B5.72B6.99B
Total Non-current Assets30.35B31.46B38.28B45.98B56.85B
Total Assets48.81B49.49B64.01B78.71B112.48B
Account Payables1.67B1.93B2.6B3.23B5.38B
Short-term Debt1.54B1.5B6.9B5.12B1.64B
Tax Payables126.9M475.1M3.85B05.88B
Deferred Revenue00000
Other Current Liabilities10.68B3.91B4.93B7.15B28.21B
Total Current Liabilities15.05B17.14B27.29B28.38B35.23B
Long-term Debt15.35B14.74B18.32B28.53B40.87B
Deferred Tax Liabilities1.73B87.3M000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities7.52B6.75B7.53B7.54B9.85B
Total Non-current Liabilities24.6B21.58B25.85B36.07B50.71B
Total Liabilities39.65B38.71B53.14B64.44B85.94B
Common Stock596.3M594.1M593.6M592.4M590M
Retained Earnings8.96B10.04B10.31B13.55B24.47B
Accumulated OCI(4.34B)(3.84B)(4.33B)(4.32B)(2.88B)
Other Stockholders Equity(3.01B)(3.01B)(3.01B)(3.01B)(2.99B)
Minority Interest175.6M125.6M91.8M79.5M0
Total Equity9.15B10.78B10.86B14.27B26.54B
Total Debt16.88B16.24B25.23B33.64B42.5B
Net Debt13.07B14.17B22.41B30.38B35.34B

Eli Lilly and Company

NYSE:LLY

Intrinsic Alpha fair value

Locked

Current Price

$1,382.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.